It has been shown previously that immunization of animals with recombinant virus-like particles (VLPs) consisting of the viral capsid proteins L1 or L1 plus L2 protected animals against experimental viral challenge. However, none of these experimental models addresses the issue of whether systemic immunization with VLPs elicits a neutralizing antibody response in the genital mucosa. Such a response may be necessary to protect the uterine cervix against infection with genital human papillomavirus (HPV) types. African green monkeys systemically immunized with HPV-11 VLPs expressed in Saccharomyces cerevisiae and formulated on aluminum adjuvant elicited high-titered HPV-11 VLP -specific serum antibody responses. Sera from these immunized monkeys neutralized HPV-11 in the athymic mouse xenograft system. Significant levels of HPV-11 -neutralizing antibodies also were observed in cervicovaginal secretions. These findings suggest that protection against HPV infection of the uterine cervix may be possible through systemic immunization with HPV VLPs.
Human papillomaviruses (HPVs) infecting genital, respiracould prevent HPV infection or reduce the virus load to levels at which disease cannot manifest itself. tory, and cutaneous epithelia cause a range of disease states, including asymptomatic carriage of virus, condyloma acumiVaccine development has been slowed by the inability to grow HPV in tissue culture or to infect species other than nata (genital warts), dysplasia, and overtly malignant lesions of the uterine cervix. From Ç80 HPV types identified thus far, humans. Only HPV-11 has been successfully propagated in the athymic mouse xenograft system developed by Kreider and HPV-6 and -11 cause ú90% of condyloma acuminata, and HPV-16 and -18 cause up to Ç90% of cervical carcinomas colleagues [5, 6] . It has been clearly demonstrated in this model that HPV-11 infection is dependent on the viral capsid protein [1 -3] . The incidence of cervical cancer in the United States L1 [7] . Expression of L1 alone or with the minor capsid protein is Ç14,000 cases/year. The rate of cervical cancer is much L2 in recombinant systems results in the formation of virus-like higher in most underdeveloped countries, where access to rouparticles (VLPs) that resemble native virions [8] . Immunization tine cervical cytologic screening is nonexistent or difficult.
with these VLPs elicits virus-neutralizing antibodies that recogWorldwide, Ç500,000 cases of invasive cervical carcinoma nize conformational epitopes on the surface of native virions are diagnosed annually, and Ç200,000 women will die each and VLPs [7] . We and others have demonstrated, in animal year from this disease [4] . Treatment for most clinically apparpapillomavirus models, that vaccination with recombinant ent HPV-related lesions is limited to physical or chemical deVLPs does prevent disease after experimental challenge [9 -struction of visible lesions and is often ineffective because of 11]. However, none of these models is adequate to address the recurrence. Therefore, a prophylactic vaccine is needed that question of whether systemic immunization is sufficient to elicit protective antibody responses in the genital mucosa or whether mucosal immunity is required. Obtaining this information will be crucial in HPV vaccine design. We therefore chose African JID 1997;176 (November) tially as described by Hofmann et al. [13] . HPV-11 and -16 VLPs Gaithersburg, MD) containing penicillin, streptomycin, and amphotericin B. The amount of HPV-11 used in each neutralization were purified from yeast lysates by the purification method described by Jansen et al. [10] with slight modifications. The purity of the assay was quantified by the HPV-11 VLP-specific RIA, with use of highly purified, yeast-derived HPV-11 VLPs as standards. Cersamples was ú95% as assessed by SDS-PAGE and colloidal Coomassie staining. VLPs reacted with a panel of monoclonal antibodies vicovaginal lavage samples were first sterile-filtered through 0.22 mm MILLEX-GV 13 (Millipore, Bedford, MA) before adding the (MAbs) known to recognize only native virions or VLPs [7] . HPV-11 L1 VLPs and HPV-11 virions were quantified by sandwich RIA sample into the HPV-11 neutralization assay. Foreskin fragments were then implanted under the renal capsules of athymic mice as that used a polyclonal anti-HPV-11 VLP serum raised in goats as VLP capture antibody, the HPV-11 virion-specific MAb 8740 described by Kreider and colleagues [5, 6] . The mice were sacrificed 70 days after implantation. The foreskin tissue implants were (Chemicon, Tecumla, CA), and anti-mouse 125 I-labeled IgG (NEN Research Products, Boston) as the detector. HPV-16 VLPs were analyzed for HPV-11 infection by HPV-11 DNA in situ hybridization with biotinylated HPV-11 DNA probes (Digene Diagnostics, quantified by a similar assay that used a polyclonal goat anti-HPV-16 VLP serum and the HPV-16 VLP-specific MAb H16.V5 [14] .
Boltsville, MD). Typically, 2 mice (4 implants) were used for each serum dilution or cervicovaginal lavage sample. HPV-11 L1 and -16 VLPs were adsorbed to aluminum hydroxyphosphate adjuvant as described [10] .
To control for HPV-11 infection and tumor growth, 2 mice received human foreskin tissue pieces incubated with virus alone. Immunization with HPV-11 L1 VLPs. Most animals used in this study were colony-bred African green monkeys. Whenever
An assay in which §75% of recovered implants were positive for HPV-11 was considered valid, and all implants in the assay were necessary, animals were sedated with ketamine HCl (10 mg/kg intramuscularly; Fort Dodge Laboratories, Fort Dodge, IA). At included in the data analysis. weeks 0, 8, and 24, groups of 4 animals were immunized with varying amounts of HPV-11 L1 VLPs adsorbed to aluminum adju-
Results

vant by intramuscular injections deep into the quadriceps muscle
HPV-11 L1 VLP -specific antibody responses in serum of
mass (extensor group) of each leg (0.5 mL of vaccine per injection site). expressed HPV-11 L1 VLPs. To test whether systemic immumetric mean titers from cervicovaginal wash samples were calculated only from samples that were shown to be free of nization elicits HPV-11 VLP -specific IgG in the genital mucosa, cervicovaginal lavage fluids were collected from the imblood contamination. The depicted cervicovaginal lavage titers were not corrected for the dilution factor associated with the munized monkeys and analyzed by the HPV-11 L1 VLPspecific ELISA. After one dose, all animal groups had detectsampling method. HPV-11 L1 VLP -specific IgA and sIgA in the samples were below the detection limits of the assays. able HPV-11 L1 VLP -specific IgG antibodies in their cervicovaginal lavage samples (figure 1). The cervicovaginal antibody HPV-11 L1 VLP -specific IgM responses were not determined because of the low levels detected in the corresponding serum titers paralleled the responses in serum and were still present 6 months after the last booster immunization (figure 1). Geosamples.
African green monkeys immunized with yeast-expressed HPV-
Correlation of HPV-11 L1 VLP -specific IgG titers and neutralization of infectious HPV-11 virions.
To determine whether the antibody response elicited after immunization with HPV-11 VLPs was neutralizing, serial dilutions of immune and preimmune African green monkey sera were tested in the athymic mouse xenograft system. About 10 9 virions were used in each neutralization assay. Previous experiments (Brown DR, unpublished data) indicated that monkey preimmune serum samples at dilutions £1:10 were partially neutralizing. For this reason, the lowest serum dilution tested in each neutralization assay was 1:40. As shown in figure 3, serum samples with titers ú500 were found to be completely neutralizing. Serum samples with IgG titers below 500 did not fully neutralize the input virus.
The ability of HPV-11 L1 VLP immunization to successfully protect the female genital tract may require the presence of virus-neutralizing antibodies in the genital mucosa. Cervico- Although firm evidence is lacking, it is presumed that HPVs infect genital epithelium by adhering to the surface of basal cells, which become exposed by microtrauma. In the athymic xenograft system of HPV-11 infection, antibodies to conformational epitopes of HPV-11 L1 can prevent infection of human foreskin tissue, even when addition of antibodies is delayed for several hours [17] , suggesting that antibodies could protect the genital epithelium from infection. The importance of neutralizing antibodies to protect animals from papillomavirus infection has been also demonstrated by passive transfer of neutralizing antiserum [9, 11, 18] . To be fully protective against genital tract HPV infection, antibodies will need to be present at the time of exposure. Our data show that HPV-11 L1 VLP - the antigen-specific IgG detected in the cervicovaginal secretions originated from transudated serum IgG or was locally produced. However, since the cervicovaginal antibody reimplants were HPV-negative in the athymic mouse xenograft sponses closely paralleled the serum responses, it is more likely assay. More data points with higher-titered cervicovaginal samthat the HPV-11 L1 VLP -specific IgG originated from the ples are needed, however, to assess whether complete neutralserum. The HPV-11 L1 VLP -specific antibody response perization could be achieved or whether there is a qualitative sisted in serum and the cervicovaginal mucosa for ú6 months difference in the ability of these samples to neutralize. Overall, after the last booster immunization. HPV-11 VLP -specific IgG titers correlated directly with the Parenteral immunization against genital HPVs might overdegree of virus neutralization (figure 3).
come several potential obstacles associated with generating a local immune response in the genital tract. First, protein antigens are generally not very immunogenic when administered Discussion locally, necessitating frequent booster immunizations, which could potentially induce tolerance [19] . In addition, local reNonhuman primates, such as African green or Rhesus monkeys, are very useful models to evaluate the responses to potensponses against protein antigens have been generally shortlived and do not effectively induce local immune memory. On tial sexually transmitted disease vaccines because the female genital tracts and genital immune responses to antigens in these the other hand, parenteral immunization strategies have been successful in protecting from experimental rotavirus [20] and animals closely resemble those of humans [16] . Since there is no HPV disease model and the current papillomavirus animal simian immunodeficiency virus challenges [21] . Circumstantial evidence also suggests that mucosal IgG antibodies can protect models are not models of genital disease, we used nonhuman primates in conjunction with the HPV-11 athymic mouse xenoagainst viruses replicating at mucosal surfaces [22] . Despite being low-titered compared to the serum samples, graft neutralization assay to determine whether systemic immunization with yeast-derived HPV-11 L1 VLPs elicited an imthe cervicovaginal lavage samples tested were also efficiently neutralizing, albeit not completely. Considering that the HPVmune response capable of mucosal protection.
All monkeys immunized with HPV-11 L1 VLPs formulated 11 athymic mouse xenograft neutralization assay requires a large amount of HPV-11 virions (Ç10 9 particles) to ensure on aluminum adjuvant developed high-titered HPV-11 L1 VLP -specific antibodies in serum and detectable antibody tia consistent infection of human foreskin tissue (Brown DR, unpublished data) and that the lavage samples were diluted ters in their cervicovaginal secretions. HPV-11 L1 and HPV-16 L1 VLPs elicited very similar responses in the animals.
during the sampling procedure, the amounts present in the
